Abaloparatide Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 80 mcg
Reference Brands: Tymlos (USA), Eladynos (EU)
Category:
Osteoporosis
Abaloparatide is available in injection (prefilled syringe)
and strengths such as 80 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Abaloparatide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Abaloparatide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Abaloparatide is a synthetic analog of human parathyroid hormone–related peptide (PTHrP 1–34) developed for the treatment of osteoporosis, particularly in postmenopausal women who are at high risk of fractures. The amino-acid sequence of abaloparatide is identical to PTHrP in the first 20 amino acids, while several differences in the remaining sequence contribute to its unique pharmacological profile. This modification allows abaloparatide to stimulate bone formation effectively while producing relatively lower stimulation of bone resorption compared with some earlier anabolic therapies.
Abaloparatide works by activating the PTH1 receptor in bone tissue, promoting new bone formation and increasing bone mineral density (BMD). Its mechanism is associated with a more transient signaling response, which may contribute to its strong anabolic effect on bone. Clinical studies, including large phase 3 trials in postmenopausal women with osteoporosis, have shown that abaloparatide significantly reduces the risk of vertebral and non-vertebral fractures while improving bone density at important skeletal sites such as the lumbar spine, hip, and femoral neck.
Administered as a once-daily subcutaneous injection, abaloparatide represents an important anabolic treatment option for osteoporosis. It offers a promising approach for patients requiring therapies that actively build bone and help reduce fracture risk.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing